Unigene to Announce Third Quarter 2012 Financial Results on November 20, 2012
BOONTON, N.J., Nov. 16, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, announced today that management will report third quarter 2012 financial results before market opens and host a conference call and live audio webcast on Tuesday, November 20, 2012 at 11 a.m., ET.
Interested participants and investors may access the conference call at 11 a.m., ET by dialing 866-770-7129 (U.S./Canada) or 617-213-8067 (international); participant code 73538559. An audio webcast can be accessed by logging on to the Investors & Media section under the Events tab of the Unigene web site, http://www.unigene.com.
A telephonic replay of the call will be available for two weeks beginning at 1 p.m., ET on November 20. Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international); participant code 22096406. The webcast replay will remain available in the Investors section of the Unigene Laboratories web site for 30 days.
ABOUT UNIGENE LABORATORIES, INC.
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence™ encompasses extensive intellectual property covering drug delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence™ assets include proprietary oral and nasal peptide drug delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.
For Investors & Media:
Joshua Drumm , Ph.D. / Jason Rando
Tiberend Strategic Advisors, Inc.
(212) 827-0020
jdrumm@tiberend.com
jrando@tiberend.com
SOURCE Unigene Laboratories, Inc.
RELATED LINKS
http://www.unigene.com
More by this Source
Unigene Announces First Quarter 2013 Financial Results and Provides Corporate Update
May 14, 2013, 08:31 ET
Unigene and Nordic Bioscience Enter Equity Transfer and Exclusive License Agreement for Proprietary Metabolic Peptide Analogs
May 09, 2013, 08:33 ET
Victory Park Capital Completes Public Auction of Unigene's Peptelligence™ Drug Delivery Platform
Apr 17, 2013, 17:16 ET
Featured Video
Journalists and Bloggers
Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.
View and download archived video content distributed by MultiVu on The Digital Center.
Custom Packages
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.